[{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Simoctocog Alfa","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma \/ Not Applicable"},{"orgOrder":0,"company":"H\u00e4mophilie-Zentrum Rhein Main","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Simoctocog Alfa","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"H\u00e4mophilie-Zentrum Rhein Main","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma","highestDevelopmentStatusID":"12","companyTruncated":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Simoctocog Alfa","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Simoctocog Alfa

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : NUWIQ is a recombinant antihemophilic factor [coagulation factor VIII] indicated in adults and children with Hemophilia A for treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequenc...

Brand Name : Nuwiq

Molecule Type : Peptide

Upfront Cash : Not Applicable

July 05, 2021

Lead Product(s) : Simoctocog Alfa

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Hämophilie-Zentrum Rhein Main

Country arrow
BIO Partnering at JPM
Not Confirmed

Hämophilie-Zentrum Rhein Main

Country arrow
BIO Partnering at JPM
Not Confirmed

Details : MOTIVATE trial comprised regimens of human cell line-derived recombinant FVIII Nuwiq® or the plasma-derived FVIII products octanate® or wilate® for the management of patients with hemophilia A and inhibitors.

Brand Name : Nuwiq

Molecule Type : Large molecule

Upfront Cash : Not Applicable

May 28, 2021

Lead Product(s) : Simoctocog Alfa

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Octapharma

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The NuProtect study was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®.

Brand Name : Nuwiq

Molecule Type : Large molecule

Upfront Cash : Not Applicable

February 22, 2021

Lead Product(s) : Simoctocog Alfa

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank